With this respect, all patients of our cohort with oncogenic alterations within the MAPK pathway (KRAS and NRAS) presented skin tumors at any time point during disease course, and the NRAS-mutated patient progressed from extensive tumor stage to systemic dissemination. This evidence concerns the gene KRAS and neoplasm.